Cargando…

Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives

SIMPLE SUMMARY: Management of gastrointestinal (GI) cancers t is a worldwide challenge and some new tools are needed to guide it. Circulating tumor DNA (ctDNA) is a fraction of tumor DNA that can be detected by a liquid biopsy through a simple blood sample. In this work, we tried to summarize in a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Moati, Emilie, Taly, Valerie, Garinet, Simon, Didelot, Audrey, Taieb, Julien, Laurent-Puig, Pierre, Zaanan, Aziz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507552/
https://www.ncbi.nlm.nih.gov/pubmed/34638228
http://dx.doi.org/10.3390/cancers13194743
_version_ 1784581883091222528
author Moati, Emilie
Taly, Valerie
Garinet, Simon
Didelot, Audrey
Taieb, Julien
Laurent-Puig, Pierre
Zaanan, Aziz
author_facet Moati, Emilie
Taly, Valerie
Garinet, Simon
Didelot, Audrey
Taieb, Julien
Laurent-Puig, Pierre
Zaanan, Aziz
author_sort Moati, Emilie
collection PubMed
description SIMPLE SUMMARY: Management of gastrointestinal (GI) cancers t is a worldwide challenge and some new tools are needed to guide it. Circulating tumor DNA (ctDNA) is a fraction of tumor DNA that can be detected by a liquid biopsy through a simple blood sample. In this work, we tried to summarize in a clinical review to what extend the analysis of ctDNA can improve therapeutic support in digestive oncology and how this circulating biomarker appears as a very promising improvement in addition to classic diagnostic, prognostic and theranostic methods. Although the level of evaluation of this tool is still different between the different GI cancers locations, it is in dynamic evolution in all of them. ABSTRACT: Gastrointestinal (GI) cancers are major health burdens worldwide and biomarkers are needed to improve the management of these diseases along their evolution. Circulating tumor DNA (ctDNA) is a promising non-invasive blood and other bodily-fluid-based biomarker in cancer management that can help clinicians in various cases for the detection, diagnosis, prognosis, monitoring and personalization of treatment in digestive oncology. In addition to the well-studied prognostic role of ctDNA, the main real-world applications appear to be the assessment of minimal residual disease to further guide adjuvant therapy and predict relapse, but also the monitoring of clonal evolution to tailor treatments in metastatic setting. Other challenges such as predicting response to treatment including immune checkpoint inhibitors could also be among the potential applications of ctDNA. Although the level of advancement of ctDNA development in the different tumor localizations is still inhomogeneous, it might be now reliable enough to be soon used in clinical routine for colorectal cancers and shows promising results in other GI cancers.
format Online
Article
Text
id pubmed-8507552
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85075522021-10-13 Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives Moati, Emilie Taly, Valerie Garinet, Simon Didelot, Audrey Taieb, Julien Laurent-Puig, Pierre Zaanan, Aziz Cancers (Basel) Review SIMPLE SUMMARY: Management of gastrointestinal (GI) cancers t is a worldwide challenge and some new tools are needed to guide it. Circulating tumor DNA (ctDNA) is a fraction of tumor DNA that can be detected by a liquid biopsy through a simple blood sample. In this work, we tried to summarize in a clinical review to what extend the analysis of ctDNA can improve therapeutic support in digestive oncology and how this circulating biomarker appears as a very promising improvement in addition to classic diagnostic, prognostic and theranostic methods. Although the level of evaluation of this tool is still different between the different GI cancers locations, it is in dynamic evolution in all of them. ABSTRACT: Gastrointestinal (GI) cancers are major health burdens worldwide and biomarkers are needed to improve the management of these diseases along their evolution. Circulating tumor DNA (ctDNA) is a promising non-invasive blood and other bodily-fluid-based biomarker in cancer management that can help clinicians in various cases for the detection, diagnosis, prognosis, monitoring and personalization of treatment in digestive oncology. In addition to the well-studied prognostic role of ctDNA, the main real-world applications appear to be the assessment of minimal residual disease to further guide adjuvant therapy and predict relapse, but also the monitoring of clonal evolution to tailor treatments in metastatic setting. Other challenges such as predicting response to treatment including immune checkpoint inhibitors could also be among the potential applications of ctDNA. Although the level of advancement of ctDNA development in the different tumor localizations is still inhomogeneous, it might be now reliable enough to be soon used in clinical routine for colorectal cancers and shows promising results in other GI cancers. MDPI 2021-09-22 /pmc/articles/PMC8507552/ /pubmed/34638228 http://dx.doi.org/10.3390/cancers13194743 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Moati, Emilie
Taly, Valerie
Garinet, Simon
Didelot, Audrey
Taieb, Julien
Laurent-Puig, Pierre
Zaanan, Aziz
Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives
title Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives
title_full Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives
title_fullStr Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives
title_full_unstemmed Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives
title_short Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives
title_sort role of circulating tumor dna in gastrointestinal cancers: current knowledge and perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507552/
https://www.ncbi.nlm.nih.gov/pubmed/34638228
http://dx.doi.org/10.3390/cancers13194743
work_keys_str_mv AT moatiemilie roleofcirculatingtumordnaingastrointestinalcancerscurrentknowledgeandperspectives
AT talyvalerie roleofcirculatingtumordnaingastrointestinalcancerscurrentknowledgeandperspectives
AT garinetsimon roleofcirculatingtumordnaingastrointestinalcancerscurrentknowledgeandperspectives
AT didelotaudrey roleofcirculatingtumordnaingastrointestinalcancerscurrentknowledgeandperspectives
AT taiebjulien roleofcirculatingtumordnaingastrointestinalcancerscurrentknowledgeandperspectives
AT laurentpuigpierre roleofcirculatingtumordnaingastrointestinalcancerscurrentknowledgeandperspectives
AT zaananaziz roleofcirculatingtumordnaingastrointestinalcancerscurrentknowledgeandperspectives